← Leaderboards
Gale Smith
Novavax, Inc.
$1,164,327
Attributed
$1,287,733
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $509.6K · FY2005–09$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
Funding mix
By agency
NIH$1,287,733 · 2
By mechanism
U01$1,040,921 · 1
R43$246,812 · 1
Top collaborators
- Penny M. Heaton1 shared
Others in their field
Top investigators on “Safety”
- David Heimbrook · Leidos Biomedical Research, Inc.$398,099,186
- Lawrence Corey · Fred Hutchinson Cancer Center$396,952,463
- Mitchell J Malone · Texas A&M Research Foundation$329,191,208
- Gary D Acton · University Of California-Davis$320,373,312
- Melynda Holmes · Technical Resources Inc$232,659,786
- Beth Baseler · Leidos Biomedical Research, Inc.$225,257,316
Research focus
SafetyVirusGlycosylationRecombinantsVaccine DevelopmentViralCellsGlycoproteinsInfectionProductionToxicologyAnimal ModelAnimalsVaccinesBuffersCell LineAntigensEvaluationBaculovirusesImmunogenicityInsectaPre-ClinicalTemperatureVirus-Like Particle
Grant awards (4)
Development of a Virus-like Particle (VLP) Vaccine for RSV$246,812
R43 · FY2009 · AI
Development of Recombinant SARS VLP Vaccines$509,590
U01 · FY2007 · AI · contact PI
Development of Recombinant SARS VLP Vaccines$270,605
U01 · FY2006 · AI · contact PI
Development of Recombinant SARS VLP Vaccines$260,726
U01 · FY2005 · AI